Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele
(2017) In Cancer Causes and Control 28(3). p.227-233- Abstract
Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios... (More)
Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele. Results: The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45–0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47–1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51–0.90; p = 0.008). Conclusions: Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.
(Less)
- author
- organization
-
- EpiHealth: Epidemiology for Health
- Molecular genetic reproductive medicine, Malmö (research group)
- Orthopedics (research group)
- Reproductive medicine, Malmö (research group)
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Urological cancer, Malmö (research group)
- publishing date
- 2017-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Androgen receptor, Genetic variants, Prostate cancer
- in
- Cancer Causes and Control
- volume
- 28
- issue
- 3
- pages
- 227 - 233
- publisher
- Springer
- external identifiers
-
- scopus:85011923808
- pmid:28176139
- wos:000394986000005
- ISSN
- 0957-5243
- DOI
- 10.1007/s10552-017-0859-1
- language
- English
- LU publication?
- yes
- id
- f00fbcbf-624c-42b4-a209-e54e2c002941
- date added to LUP
- 2017-02-27 14:29:33
- date last changed
- 2024-02-29 10:19:14
@article{f00fbcbf-624c-42b4-a209-e54e2c002941, abstract = {{<p>Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele. Results: The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45–0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47–1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51–0.90; p = 0.008). Conclusions: Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.</p>}}, author = {{Bentmar Holgersson, Magdalena and Ruhayel, Yasir and Karlsson, Magnus and Giwercman, Aleksander and Bjartell, Anders and Ohlsson, Claes and Mellström, Dan and Ljunggren, Östen and Haghsheno, Mohammad-Ali and Damber, Jan-Erik and Giwercman, Yvonne}}, issn = {{0957-5243}}, keywords = {{Androgen receptor; Genetic variants; Prostate cancer}}, language = {{eng}}, number = {{3}}, pages = {{227--233}}, publisher = {{Springer}}, series = {{Cancer Causes and Control}}, title = {{Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele}}, url = {{http://dx.doi.org/10.1007/s10552-017-0859-1}}, doi = {{10.1007/s10552-017-0859-1}}, volume = {{28}}, year = {{2017}}, }